Bortezomib (PS-341)

Catalog No.S1013

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Bortezomib (PS-341) Chemical Structure

Bortezomib (PS-341) Chemical Structure
Molecular Weight: 384.24

Validation & Quality Control

Cited by 142 publications:

20 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Proteasome Inhibitors with Unique Features

  • Pan Proteasome Inhibitor

    Ixazomib (MLN2238) β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.

  • FDA-approved Proteasome Inhibitor

    Carfilzomib (PR-171) Approved by FDA for multiple myeloma.

  • Newest Proteasome Inhibitor

    Oprozomib (ONX 0912) Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

  • Classic Proteasome Inhibitor

    ONX-0914 (PR-957) Selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome.

Product Information

  • Compare Proteasome Inhibitors
    Compare Proteasome Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.
Targets 20S proteasome [1]
(Cell-free assay)
IC50 0.6 nM(Ki)
In vitro Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MCF-7Ml3OR5l1d3SxeHnjJGF{e2G7NULnXVlxPTBizszNMX:0PEBpNUi3UnhETE2VTx?=MYTLbYxteyClZXzsd{BjgSCvb4LlJJRp[W5iOUmlM3XDNlExPDl7NkSz
OVCA 429MWnGeY5kfGmxbjDBd5NigQ>?NVzSToc6OzByIH7NMUK0PEBpMnnNSG1UVw>?MVfEbZNzfXC2czDpcpRi[3RibYXseIlk\WyudXzhdkB1fW2xcjDzdIhmem:rZIO=MmLkNVA6QTl5Nk[=
RPMI8226NGjDRW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLsUppHOTByIH7NNWDUSlBvPDhiaB?=MnfsSG1UVw>?NUCxV3ozUUN3ME2zNEBvVQ>?MlP1NVE{ODZ2OEm=
Dox40MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LvOFExOCCwTR?=MX[0PEBpNIG1SoRFVVORM3vZeGlEPTB;NECgcm0>NYPNOXlQOTF|ME[0PFk>
MR20NGTRPW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zZfFExOCCwTR?=MUO0PEBpNWLOcppUTE2VTx?=MWnJR|UxRTJyIH7NMnHnNVE{ODZ2OEm=
LR5M4X6R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1f5UVExOCCwTR?=M3XkWFQ5KGh?NX;6SnBoTE2VTx?=M3ywdWlEPTB;MkCgcm0>M3TX[FEyOzB4NEi5
U266NUDMeYRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHmNVAxKG6PNEjpc3k1QCCqM{fCPGROW09?NX7oc4hWUUN3ME2zJI5OMVSxNVMxPjR6OR?=
IM-9M{L6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmfrNVAxKG6PMWK0PEBpNFzYNlhFVVORNX3YcVhmUUN3ME22JI5OMkn4NVE{ODZ2OEm=
Hs SultanM1\pN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXGNVAxKG6PM4jUU|Q5KGh?NUfwUIZqTE2VTx?=NYntTnQ2UUN3ME2yNEBvVQ>?NXLHSWZQOTF|ME[0PFk>
PAM-LY2MX3GeY5kfGmxbjDBd5NigQ>?MVOxNFAhdk1?M1;nTlEzKGh?MWTEUXNQNF20[3BKdmirYnn0d{BPTi4QulKgZYN1cX[jdHnvci=>NYn2bIRGOTF|NUC5NVM>
PAM 212MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PheVExOCCwTR?=MlLkO|IhcA>?MnfFSG1UVw>?NV7j[ZBmUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm=Mm[2NVE{PTB7MUO=
PAM-LY2MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVr6OZZxOTByIH7NM2PKRlczKGh?NFH3TFNFVVORNV3VfWtNUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm=MYixNVM2ODlzMx?=
B4B8MkHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3aZpNqOTByIH7NMV:3NkBpNGPXbGpFVVORMoDlTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl?NHnMT2YyOTN3MEmxNy=>
B7E3MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jqZVExOCCwTR?=MmGwO|IhcA>?NG\LN3pFVVORMlLlTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl?MXuxNVM2ODlzMx?=
UM-SCC-9NUHyTVNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zCOFExOCCwTR?=MYO3NkBpNUPPc|U3TE2VTx?=NV7tWW06UW6qaXLpeJMh[2WubDD2bYFjcWyrdIm=Mn3uNVE{PTB7MUO=
UM-SCC-11BNIXlNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTpNVAxKG6PM3vzdFczKGh?Mk\kSG1UVw>?MWfJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?NWezdplZOTF|NUC5NVM>
H460Mm\XSpVv[3Srb36gRZN{[Xl?MYCxNEDPxE1?NE\TNGszPCCqNH3BeYlFVVORNFvm[GZKdmS3Y3XzJGJkdC1{IIDoc5NxcG:{eXzheIlwdiCjbnSgZ4xm[X[jZ3WgZ49zemWuYYTl[EB4cXSqIFeyMW0heGijc3WgZZJz\XO2MnztNVI1QTJzMUe=
U266MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1\PdFUxOCCwZz;tcC=>MlPiOFghcA>?MmL3SG1UVw>?NVHDR4V6UW6qaXLpeJMh[2WubDDndo94fGh?NXzWRWZnOTJ4M{G2NVk>
ARH77MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnhOnlXPTByIH7nM41tMVi0PEBpNYfWcodoTE2VTx?=MXPJcohq[mm2czDj[YxtKGe{b4f0bC=>MUexNlY{OTZzOR?=
WAD-1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIWyVno2ODBibnevcYw>NGP1N2Y1QCCqNITTV4dFVVORNITvTZpKdmirYnn0d{Bk\WyuIHfyc5d1cA>?Mke3NVI3OzF4MUm=
U266/LR7M3\lN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHH3O5I2ODBibnevcYw>NVnjWIpLPDhiaB?=NXO0N4hRTE2VTx?=MYDJcohq[mm2czDj[YxtKGe{b4f0bC=>M4TEZVEzPjNzNkG5
U266/dox4M{\hZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXvKVFBOPTByIH7nM41tNV62OmVQPDhiaB?=NUP2OppoTE2VTx?=MmrjTY5pcWKrdIOgZ4VtdCCpcn;3eIg>MXKxNlY{OTZzOR?=
RPMI8226/LR5MmnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MliwOVAxKG6pL33sMnviOFghcA>?M4rr[mROW09?NGruT41KdmirYnn0d{Bk\WyuIHfyc5d1cA>?Ml\YNVI3OzF4MUm=
H460NHP3VYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUO0OnQ{OTBizszNNH:1S|I4OiCqNHfOUW5FVVORMWrJR|UxRTFyMDDuUS=>MYmxNlY{OTZ{MB?=
H358MlTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVy4fmNzOTBizszNMlnvO|IhcA>?NXfqXmxJTE2VTx?=MYTJR|UxRTdyIH7NM3fr[|EzPjNzNkKw
H322M4L0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV:xNEDPxE1?MV[3NkBpNEXrZ2VFVVORNF;jUFJKSzVyPU[yNEBvVQ>?NUfscIZVOTJ4M{G2NlA>
H460NW\WXZBXTnWwY4Tpc44hSXO|YYm=NGDVWIwyODBibl2=NYm4b443OjRiaB?=MnXDSG1UVw>?M4rRRmlv\HWlZYOgS|IuVS2yaHHz[UBienKnc4SgZY5lKHS3YoXsbY4h[XO|ZX3icJku\Gm|YYPz[Y1jdHl?M17DcVEzPjNzNkKw
LNCap-Pro5Mk[3SpVv[3Srb36gRZN{[Xl?M1LoN|Eh|ryPM1\QfFQhcA>?NEmxbGRFVVORM4SzOHN1[WKrbHn6[ZMheDV|NYS3bmd7OTR4MUK1N|I>
T29NXr1W486SXCxcITvd4l{KEG|c3H5MonPOVAhdk1?MlXMOFghcCB?M2DadmROW09?NGDZXItKdmS3Y3XzJINmdGxiYYDvdJRwe2m|MVqxOlc4QDF5OR?=
T29Kt1NWjuUWFoSXCxcITvd4l{KEG|c3H5MmT0OVAhdk1?MUO0PEBpKA>?MlOwSG1UVw>?MnvjTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?MYixOlc4QDF5OR?=
HCT116NUDINW5lSXCxcITvd4l{KEG|c3H5M3HRbFUxKG6PNXjVeZRGPDhiaDC=M{fiSmROW09?NWLPXWRMUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=M3:2TlE3Pzd6MUe5
HKe-3MYjBdI9xfG:|aYOgRZN{[Xl?M1j2SlUxKG6PM{X2XVQ5KGhiNVLTUXZjTE2VTx?=NUSycWU{UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=NFriNpkyPjd5OEG3PS=>
NB-1691MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\E[lVvOSEQvF2=NXPudGd5PzJiaB?=MnfRTY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDVnMWWxO|Y5QTZ6NB?=
CHLA-255M{\ZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV7qVohsOSEQvF2=MorsO|IhcA>?MUTJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOiV?M{H3eFE4Pjh7Nki0
SK-N-ASMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXGxJO69VQ>?NFjZVlU4OiCqNELCXFhKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iMUClMVKxO|Y5QTZ6NB?=
NB-1691MoDxSpVv[3Srb36gRZN{[Xl?M2P3Z|ExKG6PNFy3bFQzPCCqMWnTbYdvcW[rY3HueIx6KHKnZIXj[ZMh[2WubIOgbY4hfGinIFewM2cyKHCqYYPlMWWxO|Y5QTZ6NB?=
CHLA-255NXHDPVluTnWwY4Tpc44hSXO|YYm=M2L5UFExKG6PNWPp[lBmOjRiaB?=MlToUY9l\XO2bImgdoVlfWOnczDj[YxteyCrbjD0bIUhTzBxR{GgdIhie2V?M4XzTVE4Pjh7Nki0
RPMI 8226MUjGeY5kfGmxbjDBd5NigQ>?M1vOfFIxKG6PMlHTPEBpNWTVToduW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl?MXuxPVQ{PjB3MB?=
MM.1SM3;NPWZ2dmO2aX;uJGF{e2G7NYr4OIFZOjBibl2=NGm0TVU5KGh?MVLTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=>NYPVTWNvOTl2M{[wOVA>
U266Mnf1SpVv[3Srb36gRZN{[Xl?MYqyNEBvVQ>?NWHVVGVtQCCqMU\TbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=>M3m2elE6PDN4MEWw
OPM1NFzsVGFHfW6ldHnvckBCe3OjeR?=MWiyNEBvVQ>?MXS4JIg>NYizW|M1W2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl?MV[xPVQ{PjB3MB?=
INA6MWLGeY5kfGmxbjDBd5NigQ>?M17DO|IxKG6PNVTu[2J6QCCqMYjTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=>MVmxPVQ{PjB3MB?=
OPM2NV20clNkTnWwY4Tpc44hSXO|YYm=M2DoUFIxKG6PMmDzPEBpMV7TbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=>NYPtTlE{OTl2M{[wOVA>
RPMI 8226M2DYWmZ2dmO2aX;uJGF{e2G7Mm\MNlAhdk1?MnfaPEBpNVnSblFtUW6mdXPld{BFVkFic4nueIhme2m|MknkNVk1OzZyNUC=
BaF/3MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mli4NVAxKG6PMo\LOFghcA>?NYHQfGNRUUN3ME22MlIhdk1?MYOyNFMxPTZ7Mh?=
BaF/3-p210MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlftNVAxKG6PMnH4OFghcA>?NWTZdWtjUUN3ME20Mlchdk1?MUKyNFMxPTZ7Mh?=
TCC-SMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFrlfHUyODBibl2=M17vUlQ5KGh?MnrVTWM2OD1{Lkigcm0>NVvUN4JvOjB|MEW2PVI>
BaF/3MkHJSpVv[3Srb36gRZN{[Xl?NWTRdnlIPiCwTR?=NGPafJY1QCCqMWrJcoR2[2W|IHGg[5Jm[XRiR{GgZ4VtdC2leXPs[UBienKnc4S=MYWyNFMxPTZ7Mh?=
BaF/3-p210NWT1dmJ[TnWwY4Tpc44hSXO|YYm=MXq2JI5ONXvhRpI3PDhiaB?=MV7JcoR2[2W|IHGgd4xq\2i2IFexJINmdGxvY4njcIUh[XK{ZYP0Mm\SNlA{ODV4OUK=
BaF/3-p210M{PNbWZ2dmO2aX;uJGF{e2G7MXe2JI5OM1HqbFI1KGh?NGLDNHVT\WS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44h[W6mIITo[UBi[3Srdnn0fUBw\iCUYh?=NHL4W4IzODNyNU[5Ni=>
RajiM1fi[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH61S5kyKM7:TR?=M2DLelI1KGh?MXXS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB?MUOyNVE4ODl6OB?=
LCL-1M3nRVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;ZO|IyKM7:TR?=MlPPNlQhcA>?MYjS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB?M33VUlIyOTdyOUi4
LCL-2NInMZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PrbVEh|ryPNIK2Nm8zPCCqMljrVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLiM4PoPVIyOTdyOUi4
BJABNGDZO29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVKxJO69VQ>?NF22bYwzPCCqMV3S[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB?M3vRWlIyOTdyOUi4
SNT-13MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFKxS2IyKM7:TR?=NEXXRXAzPCCqNVr0N2V2WmWmdXPld{Bk\WyuII\pZYJqdGm2edMgMYeyNVE4ODl6OB?=
SNT-16MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnW4NUDPxE1?NYX3PHRNOjRiaB?=NEj5UIVT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=MWWyNVE4ODl6OB?=
JurkatNH34bI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX6xJO69VQ>?NF3zOWUzPCCqM{DpbnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=NIjjR3kzOTF5MEm4PC=>
KAI-3MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\FeFEh|ryPNUnWU29UOjRiaB?=Mn3XVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLiM{PDVVIyOTdyOUi4
SNK-6NEnuN3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jOfVEh|ryPMUKyOEBpMlztVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLiNXHmNWxZOjFzN{C5PFg>
KHYG-1M3;h[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{foOVEh|ryPMVeyOEBpMUXS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB?NXznTWxDOjFzN{C5PFg>
SNT-16NV7xWYdYSXCxcITvd4l{KEG|c3H5MmXwNUDPxE1?MYe2JIg>NYWwNGEyUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=M3TJSFIyOTdyOUi4
JurkatM4n0VmFxd3C2b4Ppd{BCe3OjeR?=M3PQRVEh|ryPNGj6bpc3KGh?MYjJcoR2[2W|IHPlcIwh[XCxcITvd4l{NVvSenRbOjFzN{C5PFg>
KAI-3M4XFO2Fxd3C2b4Ppd{BCe3OjeR?=NIrrZoEyKM7:TR?=MW[2JIg>MVzJcoR2[2W|IHPlcIwh[XCxcITvd4l{NUK0XppCOjFzN{C5PFg>
KHYG-1MmqzRZBweHSxc3nzJGF{e2G7NEfTW|kyKM7:TR?=MWq2JIg>NES2UHpKdmS3Y3XzJINmdGxiYYDvdJRwe2m|NF7IXmszOTF5MEm4PC=>
SNT-13M3u3fWFvfGm4aYLhcEBCe3OjeR?=MWCxJO69VQ>?MnrJNlQhcA>?MVTJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY>NGC5WVMzOTF5MEm4PC=>
SNT-16Mni0RY51cX[rcnHsJGF{e2G7NGLBVHAyKM7:TR?=NHGzb|MzPCCqMmrrTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJXM3[wTFIyOTdyOUi4
KAI-3NFTiZY1CdnSrdnnyZYwhSXO|YYm=NXvtOIJEOSEQvF2=NXPhXGJNOjRiaB?=NYTMZYVlUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKYNGnMeoYzOTF5MEm4PC=>
SNK-6MVnBcpRqfmm{YXygRZN{[Xl?MlrPNUDPxE1?NEnnb3YzPCCqNFXDd5NKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ?MnXONlEyPzB7OEi=
RAW 264.7M2joT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1\hNVExOCCwTR?=MYS0PEBpNHXrS3dT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=MlTBNlI1OjdzNUS=
A375M{nIbmFxd3C2b4Ppd{BCe3OjeR?=NVL5O2lWOTBibl2=NHvsc4QzPCCqNHf2OpFKdmS3Y3XzJINmdGxiYYDvdJRwe2m|NHe1WWMzOzB5OUC4Ny=>
BLMMXjBdI9xfG:|aYOgRZN{[Xl?MkTKNVAhdk1?NFv6fFAzPCCqMoTvTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?M{HHPVI{ODd7MEiz
A375MmnjRZV1d3CqYXf5JGF{e2G7M2n6dlExKG6PMYOxNkBpNYPoN|V3UW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM>MlPLNlMxPzlyOEO=
BLMNInXT3BCfXSxcHjh[5khSXO|YYm=NHzmO3MyOCCwTR?=MWCxNkBpM{DLZ2lv\HWlZYOg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXzNXXSUI5WOjNyN{mwPFM>
H1299NY\yVIlPSXCxcITvd4l{KEG|c3H5MXS4NEBvVQ>?NFTvPZQzPCCqMlj3SG1UVw>?Ml3OV4Vve2m2aYrld{BPW0OOQzDj[YxteyC2bzDNV2Mu\GW{aY\l[EBqSzlvaX7keYNm\CCjcH;weI9{cXN?M2\KN|I2OzJ|Nkmz
Hut-78MVfGeY5kfGmxbjDBd5NigQ>?M1;OUFExOCCwTR?=NIfkdm8zPCCqMUTEUXNQMX3Ec5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVExKGW6cILld5Nqd25?MormNlU3QDF|M{W=
H9MlvNSpVv[3Srb36gRZN{[Xl?M3rlOVExOCCwTR?=MoHVNlQhcA>?M1;kcWROW09?Mmm1SI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOSCneIDy[ZN{cW:wNITETm0zPTZ6MUOzOS=>
HHMoSxSpVv[3Srb36gRZN{[Xl?M3GyU|ExOCCwTR?=MUWyOEBpMXTEUXNQM4rmU4Rwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTJiZYjwdoV{e2mxbh?=NX\wcXF7OjV4OEGzN|U>
Hut-78M4nFO21q\3KjdHnvckBCe3OjeR?=Mk\iNVAxKG6PMmn0NlQhcA>?MYHEUXNQNEPSWZZT\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUClMUCyOVY5OTN|NR?=
HHMXHNbYdz[XSrb36gRZN{[Xl?MmTLNVAxKG6PMWCyOEBpMnXWSG1UVw>?M3j3ZXJm\HWlZYOgZ4VtdCCvaXfyZZRqd25iYomgPFDjiJN7MTW=NX;WdYxyOjV4OEGzN|U>
U937M2HUOmZ2dmO2aX;uJGF{e2G7M{PMVVExOCCwTR?=M2TybVYhcA>?NV3Z[VkxUW6mdXPld{BKVC16IHX4dJJme3Orb36gbY4hVFCVLYP0bY12dGG2ZXSgWVk{PyCvYXPyc5Bp[Wencx?=NUDFdZozOjV5OUG0O|c>
human PBMCM1T2bWZ2dmO2aX;uJGF{e2G7NX\jfXdvOTByIH7NNGj3OGUzPCCqMXLJcoR2[2W|IFnMMVghemWuZXHz[S=>M3fhTFI2PzlzNEe3
ES6NH7O[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTBwMECyNUBvVQ>?NXrGUGRuW0GQR1XS
SK-UT-1NGj0UXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4L2b2lEPTB;MD6xOlMhdk1?NI\rWoxUSU6JRWK=
SH-4MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF3w[mFKSzVyPUCuNVc{KG6PMnO0V2FPT0WU
TE-9MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX3vS2I5UUN3ME2wMlE5OiCwTR?=NXHTT5ROW0GQR1XS
A253M3rBXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXfiOlc6UUN3ME2wMlIxQCCwTR?=M3vOXHNCVkeHUh?=
no-10NVjXU414T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnzTlRKSzVyPUCuNlEhdk1?NG\HPW5USU6JRWK=
MMAC-SFNX[2[5NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPKbIZZUUN3ME2wMlIyPiCwTR?=NGPIe2pUSU6JRWK=
A101DMnTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2LFW2lEPTB;MD6yNlUhdk1?NYXPe2trW0GQR1XS
NTERA-S-cl-D1MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTBwMkSzJI5OM4r5Z3NCVkeHUh?=
8-MG-BAMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUSzSVNOUUN3ME2wMlI2KG6PMoT0V2FPT0WU
KNS-42NVzSTGg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEjaPXFKSzVyPUCuNlU5KG6PM4DtXnNCVkeHUh?=
LXF-289MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGC3bVFKSzVyPUCuNlY6KG6PNUjyfVdkW0GQR1XS
OVCAR-4MlTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGjTbWZKSzVyPUCuNlg6KG6PMl[xV2FPT0WU
LOUCYNF\IZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\FSWlEPTB;MD6yPVMhdk1?NVLMN|g2W0GQR1XS
BB65-RCCNFXLc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLqUWZKSzVyPUCuN|A1KG6PM2f2dHNCVkeHUh?=
D-542MGNXLUfHp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3iNXRKSzVyPUCuN|I6KG6PMUTTRW5ITVJ?
ONS-76NGjMRoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTBwM{Ogcm0>MVjTRW5ITVJ?
BB30-HNCMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3ftdWlEPTB;MD6zN|Uhdk1?NFTUXFJUSU6JRWK=
KS-1NHfmOW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfWTWM2OD1yLkO0JI5OM37lc3NCVkeHUh?=
A388M1frdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnK2TWM2OD1yLkO1OkBvVQ>?M3\BZnNCVkeHUh?=
ES8MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTBwNDDuUS=>NF;K[5RUSU6JRWK=
MZ2-MELMorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTBwNEC3JI5ONIXZdG9USU6JRWK=
HCC2998NXzxe|RkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\o[5dKSzVyPUCuOFEzKG6PMWTTRW5ITVJ?
D-247MGMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmPaTWM2OD1yLkSxN{BvVQ>?M{\ZNnNCVkeHUh?=
ACNMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlrRTWM2OD1yLkSxO{BvVQ>?MXzTRW5ITVJ?
LB2518-MELM1mwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrnTWM2OD1yLkSyOUBvVQ>?M3jBcHNCVkeHUh?=
ES1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILOWnRKSzVyPUCuOFMhdk1?NU\HbIUzW0GQR1XS
HCE-TMnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnJfIJIUUN3ME2wMlQ{QSCwTR?=MoG5V2FPT0WU
OS-RC-2NIT5eJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTBwNESgcm0>M1u0UnNCVkeHUh?=
MFH-inoM33CeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLkOGlGUUN3ME2wMlQ1OyCwTR?=MVPTRW5ITVJ?
OCUB-MNUnqbZk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;sb3E2UUN3ME2wMlQ1PyCwTR?=MY\TRW5ITVJ?
CP66-MELNIjVcIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3z0TWlEPTB;MD60O|Mhdk1?NFvuRYdUSU6JRWK=
LB771-HNCNX\NSI9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPFPZFKSzVyPUCuOFc1KG6PNVnqS|FmW0GQR1XS
DSH1NFHUZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTBwNEigcm0>MkW2V2FPT0WU
HUTU-80NHTOfoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XLPGlEPTB;MD61N|Mhdk1?M1nr[3NCVkeHUh?=
CESSNIrScWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfXU5BJUUN3ME2wMlU{QCCwTR?=M4DOT3NCVkeHUh?=
NCI-H747MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFW2fodKSzVyPUCuOVM6KG6PM2C0TXNCVkeHUh?=
HT-144NEnLWXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTBwNUe2JI5OM3LNOHNCVkeHUh?=
COLO-829M2rDZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTqe|NPUUN3ME2wMlYyPCCwTR?=MnfOV2FPT0WU
A4-FukM2e2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPRTWM2OD1yLk[yN{BvVQ>?MXrTRW5ITVJ?
GI-ME-NMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTBwNkO0JI5ONXTGXIJXW0GQR1XS
LB831-BLCNF7sdYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnriTWM2OD1yLk[0NUBvVQ>?NWDuWHI2W0GQR1XS
HOP-62M1O5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUD3U2twUUN3ME2wMlY1PyCwTR?=NWHsRYwzW0GQR1XS
BB49-HNCMlToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\VNW1KSzVyPUCuOlUzKG6PMWPTRW5ITVJ?
D-336MGNFLZNlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY[5bFZ3UUN3ME2wMlY2PyCwTR?=MnfuV2FPT0WU
TK10M360NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{H2WGlEPTB;MD62O|khdk1?MnvLV2FPT0WU
Ramos-2G6-4C10M3\UUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3Xx[WlEPTB;MD62PVMhdk1?NGO3RVhUSU6JRWK=
LB373-MEL-DNUG3WJVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mof1TWM2OD1yLkegcm0>M3HrcHNCVkeHUh?=
SF126M33JXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjnemtGUUN3ME2wMlcxOSCwTR?=M1n5VnNCVkeHUh?=
UACC-257MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkiwTWM2OD1yLkexJI5OMoTjV2FPT0WU
KINGS-1NVXQUJZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTBwN{KyJI5OMXPTRW5ITVJ?
LS-513M4ruOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHnGUJRKSzVyPUCuO|M6KG6PM1HxTnNCVkeHUh?=
GI-1NGHVSXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;ueWtqUUN3ME2wMlc3PCCwTR?=MV\TRW5ITVJ?
ES7NXTrbYY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;4TWM2OD1yLke2OkBvVQ>?M3\qOXNCVkeHUh?=
LB2241-RCCNELTPWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnzyTWM2OD1yLkiwOEBvVQ>?M4XK[XNCVkeHUh?=
D-263MGMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTBwOEC3JI5OM2fxdHNCVkeHUh?=
SW684M3nvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn3tTWM2OD1yLkiyNUBvVQ>?MYLTRW5ITVJ?
ML-2M3PqNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfkfGpRUUN3ME2wMlgzOSCwTR?=M1XpZXNCVkeHUh?=
SK-LMS-1MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn7zTWM2OD1yLki1OEBvVQ>?NUf2fVFUW0GQR1XS
TE-5MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTBwOE[1JI5OMki4V2FPT0WU
QIMR-WILMl3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEnJS|ZKSzVyPUCuPFg6KG6PNX[xc5VCW0GQR1XS
NCI-H1355NILNSFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\MNYhKSzVyPUCuPFk2KG6PMUDTRW5ITVJ?
SNB75MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTBwOUGyJI5ONX:1U|QxW0GQR1XS
RXF393NGHvXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HHNGlEPTB;MD65NVQhdk1?NVXTZod1W0GQR1XS
IST-MEL1M3z0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPSNmpJUUN3ME2wMlkyPyCwTR?=NUXBUYtHW0GQR1XS
SF268MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkXyTWM2OD1yLkmyN{BvVQ>?M1PWdnNCVkeHUh?=
KALS-1MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWjaZm1sUUN3ME2wMlkzPSCwTR?=NHuyV4NUSU6JRWK=
HC-1NUHvXlVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXlfWVoUUN3ME2wMlk4PSCwTR?=MYPTRW5ITVJ?
SW872NUTTSYpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjkU2hMUUN3ME2wMlk6PiCwTR?=Mn;yV2FPT0WU
PSN1M3\oT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGr4XGRKSzVyPUGuNFEhdk1?NXzCZ|BqW0GQR1XS
TE-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTFwMEOgcm0>MkW5V2FPT0WU
TE-10NVPsRotHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTFwMEOgcm0>NImxcpBUSU6JRWK=
RKOMnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHab|dNUUN3ME2xMlA3KG6PNXTiUG1nW0GQR1XS
LC-2-adM2q2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVL5WVc2UUN3ME2xMlA5KG6PNX7mdms1W0GQR1XS
SK-MM-2NHK4O4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY\hfYt4UUN3ME2xMlA6KG6PNITqVoNUSU6JRWK=
VA-ES-BJM4Piemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;4TWM2OD1zLkC5JI5OM{TSXXNCVkeHUh?=
MZ7-melNXj6XIRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2T6OWlEPTB;MT6wPUBvVQ>?NHzZfnZUSU6JRWK=
D-392MGNGrYblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnjTWM2OD1zLkGgcm0>MUnTRW5ITVJ?
CCRF-CEMMnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVTwe2pwUUN3ME2xMlE{KG6PMVnTRW5ITVJ?
EM-2M4W5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPmRWRKSzVyPUGuNVYhdk1?NVzDUFJsW0GQR1XS
HAL-01NEnwd4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVSybGg6UUN3ME2xMlE5KG6PNHW5Z2xUSU6JRWK=
TE-8MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWfWVodOUUN3ME2xMlE6KG6PMVXTRW5ITVJ?
NCI-H1882M{ft[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnn6TWM2OD1zLkKgcm0>Mn7DV2FPT0WU
DaudiM4rMWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTFwMkKgcm0>M{nNfHNCVkeHUh?=
BL-41NXrvZVF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTMNVdZUUN3ME2xMlI2KG6PNX3LXXZlW0GQR1XS
SRNWS5OW4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkfsTWM2OD1zLkK1JI5OM1PlNnNCVkeHUh?=
KM12MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWjHXoFZUUN3ME2xMlI4KG6PMUfTRW5ITVJ?
K5NFH5dFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3PFPWlEPTB;MT6yPEBvVQ>?Mk\LV2FPT0WU
A3-KAWNG\rXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULj[2dYUUN3ME2xMlI5KG6PNF3S[lZUSU6JRWK=
CMKNWDMVmhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHnweYJKSzVyPUGuNlkhdk1?MYTTRW5ITVJ?
Calu-6MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTFwMkmgcm0>NVHse3VUW0GQR1XS
IST-SL2MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnXGTWM2OD1zLkOxJI5OM2W2cXNCVkeHUh?=
OPM-2M4HINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDWPJlKSzVyPUGuN|Mhdk1?NFTxPVFUSU6JRWK=
DU-4475M3PYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TWc2lEPTB;MT6zOkBvVQ>?NEjMN5BUSU6JRWK=
ECC12M3\PZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;tcI1KSzVyPUGuN|chdk1?MWDTRW5ITVJ?
L-540MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTFwM{egcm0>MnTVV2FPT0WU
CAS-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkWyTWM2OD1zLkO3JI5ONXWzc2hoW0GQR1XS
PF-382NUXufIF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTFwNEegcm0>NV3BfWVPW0GQR1XS
LS-411NNHTkXlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTFwNUOgcm0>Mnv1V2FPT0WU
NCI-H69NGDPcVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHvm[G9KSzVyPUGuOVQhdk1?NEC0dXRUSU6JRWK=
NB12MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnLsTWM2OD1zLkW2JI5ONESxelhUSU6JRWK=
HELMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnfhTWM2OD1zLk[xJI5ONV25SGQyW0GQR1XS
GCIYMmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\GSnNKSzVyPUGuOlIhdk1?NXvBfnBRW0GQR1XS
EHEBNF31b5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTFwNkegcm0>M3jhSHNCVkeHUh?=
TGBC1TKBNEHi[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDje4tKSzVyPUGuO|Ehdk1?MYDTRW5ITVJ?
KURAMOCHIMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3tdFdbUUN3ME2xMlczKG6PMWTTRW5ITVJ?
U-266M4X2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTFwN{[gcm0>MnjUV2FPT0WU
LC4-1Mn;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTFwN{mgcm0>NFWzSZFUSU6JRWK=
NCI-H2126MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPhR|VKSzVyPUGuPEBvVQ>?M1PnVHNCVkeHUh?=
NCI-H1092MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX3xU3VPUUN3ME2xMlghdk1?M4nnRXNCVkeHUh?=
GB-1M4f2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHSwSYZKSzVyPUGuPFEhdk1?NGDhPVVUSU6JRWK=
MV-4-11NV:zWHVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DWeWlEPTB;MT64NkBvVQ>?M4K3fnNCVkeHUh?=
BeckerNFOzU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHETWM2OD1zLkizJI5ONFnBcVhUSU6JRWK=
MPP-89Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHIe|A{UUN3ME2xMlg6KG6PMVfTRW5ITVJ?
BE-13NEO0VppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTFwOUOgcm0>NIS3TGNUSU6JRWK=
697NULFWVZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGTXcm1KSzVyPUGuPVkhdk1?Mn:2V2FPT0WU
NKM-1NWrIemw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3fQc2lEPTB;MjDuUS=>MoXBV2FPT0WU
NB13Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFXzdo1KSzVyPUKgcm0>NXfGeHRDW0GQR1XS
LS-123NU[wdndMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHhTWM2OD1{LkCyJI5OM1PJenNCVkeHUh?=
NB17M{nrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTJwMESgcm0>MnPjV2FPT0WU
LAN-6NW\ZUHNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TsNmlEPTB;Mj6wOUBvVQ>?MmrMV2FPT0WU
EW-24NEjIRoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHTjellKSzVyPUKuNFghdk1?MWLTRW5ITVJ?
NOS-1MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTJwMUGgcm0>NYPkZ256W0GQR1XS
BL-70NFjLNJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLjTWM2OD1{LkGyJI5OMlj0V2FPT0WU
GT3TKBMkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoruTWM2OD1{LkGyJI5ONUK1SYNjW0GQR1XS
HHNYPtWYczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{H6ZWlEPTB;Mj6xN{BvVQ>?NVHjXHhbW0GQR1XS
KE-37M2DTNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3yTWM2OD1{LkGzJI5ONYWzNJBYW0GQR1XS
MOLT-4NF7HOVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTJwMUOgcm0>MVHTRW5ITVJ?
EKVXMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4rYUWlEPTB;Mj6xOEBvVQ>?MWjTRW5ITVJ?
KGNMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DSO2lEPTB;Mj6xOUBvVQ>?NE\veVdUSU6JRWK=
ES4NF\KXWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTSTW9wUUN3ME2yMlE3KG6PMXrTRW5ITVJ?
SJSA-1NXvYWGJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2D1eGlEPTB;Mj6yNUBvVQ>?M3LiXnNCVkeHUh?=
KMOE-2NWn3VFZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4DCdWlEPTB;Mj6yN{BvVQ>?MW\TRW5ITVJ?
NB5MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDQdJVqUUN3ME2yMlI4KG6PNVnmWItPW0GQR1XS
BC-1MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlrZTWM2OD1{LkOxJI5OM{T2VHNCVkeHUh?=
NB10NIf1d|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{TWbmlEPTB;Mj6zNkBvVQ>?MUHTRW5ITVJ?
RPMI-8226NVXoTYh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHjtUlRKSzVyPUKuN|Uhdk1?MmP2V2FPT0WU
SCC-3NFPvd5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLDTWM2OD1{LkO3JI5OMYTTRW5ITVJ?
ARH-77MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoixTWM2OD1{LkO4JI5OMYrTRW5ITVJ?
NCI-H748MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHm2T|lKSzVyPUKuN|khdk1?NXy5[nB4W0GQR1XS
KU812MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4rieGlEPTB;Mj60NkBvVQ>?NV\4ZlZkW0GQR1XS
NCI-H64NEXid3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\KUWlEPTB;Mj60OEBvVQ>?NXPod2Y6W0GQR1XS
NB69NILr[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\6[mxKSzVyPUKuOFYhdk1?MoW1V2FPT0WU
KNS-81-FDNFexe4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M124d2lEPTB;Mj60PEBvVQ>?Mn7zV2FPT0WU
LB1047-RCCM{HGVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTJwNUegcm0>NXTtOId4W0GQR1XS
EB-3M1HzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTJwNk[gcm0>NWTpVHJWW0GQR1XS
Mo-TMojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTJwN{Sgcm0>M325fXNCVkeHUh?=
EW-16NFn0TmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmTZTWM2OD1{Lke1JI5OMmThV2FPT0WU
CTV-1NXHZ[FhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTJwODDuUS=>NIDodnNUSU6JRWK=
ETK-1MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFXPT4dKSzVyPUKuPFQhdk1?MXvTRW5ITVJ?
C2BBe1NEfNcYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXXTWM2OD1{Lki5JI5ONEP3RY1USU6JRWK=
MOLT-16NEnkeJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTJwOEmgcm0>NInlSYFUSU6JRWK=
SW954MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlfuTWM2OD1{Lkmgcm0>NEHCbnpUSU6JRWK=
HTM1rHXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTNwMEKgcm0>M1jtTHNCVkeHUh?=
KARPAS-299MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXLR41KSzVyPUOuNFYhdk1?MVXTRW5ITVJ?
MONO-MAC-6NILZRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYjJR|UxRTNwMTDuUS=>NEHJUWVUSU6JRWK=
CGTH-W-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUHYZlB5UUN3ME2zMlEhdk1?NXLHcZM6W0GQR1XS
SK-PN-DWMkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHqTWM2OD1|LkG0JI5OMVLTRW5ITVJ?
CW-2M4XsNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfpS2doUUN3ME2zMlIyKG6PM2\ZTnNCVkeHUh?=
SK-N-DZM4DRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXrEbIxjUUN3ME2zMlI3KG6PM3X0VXNCVkeHUh?=
NEC8MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnvrTWM2OD1|LkO1JI5OM3fibXNCVkeHUh?=
LB996-RCCNYP5fo1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTNwNDDuUS=>NIjmd4NUSU6JRWK=
DBNEf3NFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTNwNEGgcm0>MnfTV2FPT0WU
TE-15MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rIXmlEPTB;Mz60N{BvVQ>?MYTTRW5ITVJ?
COR-L88NInrfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXvXHVKSzVyPUOuOFchdk1?NUfjSJpOW0GQR1XS
LAMA-84Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mke5TWM2OD1|LkS5JI5OMVPTRW5ITVJ?
MEG-01NVfMVJR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFf2OpVKSzVyPUOuOFkhdk1?M{\hWHNCVkeHUh?=
LOXIMVINFTMZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHDfWFQUUN3ME2zMlUhdk1?M1Lib3NCVkeHUh?=
RPMI-8402M1fib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlK1TWM2OD1|LkWgcm0>NXntPIltW0GQR1XS
KARPAS-45NYLI[GJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTNwNUSgcm0>NFf4dppUSU6JRWK=
HCC1187NYjmVmFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTNwNUSgcm0>M1\rW3NCVkeHUh?=
MZ1-PCNWezWHZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTNwNUSgcm0>M3LtWXNCVkeHUh?=
no-11MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTNwNUWgcm0>MULTRW5ITVJ?
EVSA-TNGrnOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zVbGlEPTB;Mz62JI5OM1vEfnNCVkeHUh?=
DJM-1MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXv5[HhkUUN3ME2zMlY{KG6PMkPQV2FPT0WU
COLO-684MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjmWFRNUUN3ME2zMlY3KG6PM1LHPHNCVkeHUh?=
NMC-G1M{DRWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\rcGlEPTB;Mz62PEBvVQ>?NUPpc4FXW0GQR1XS
LC-1FNVu3XmFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLXTWM2OD1|Lke0JI5OM2nsd3NCVkeHUh?=
RL95-2M2L1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\KNlBKSzVyPUOuO|khdk1?MXTTRW5ITVJ?
COLO-320-HSRMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXnsbIs4UUN3ME2zMlkzKG6PNUT3WHpVW0GQR1XS
RCC10RGBNH2yUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTNwOUOgcm0>NFf4d5BUSU6JRWK=
HD-MY-ZNG[2XHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTNwOUOgcm0>NFnUbnpUSU6JRWK=
NCI-H2141MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;ndWlDUUN3ME20MlA2KG6PMnnhV2FPT0WU
K-562MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;jc2lEPTB;ND6xNkBvVQ>?M4D4bHNCVkeHUh?=
NCI-H1648NW\FWGY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfqTFBWUUN3ME20MlE{KG6PNFzzVIVUSU6JRWK=
OMC-1M37tRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmL0TWM2OD12LkG4JI5ONXPkW3V2W0GQR1XS
LB647-SCLCMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHXWWNKSzVyPUSuNlIhdk1?M4PNO3NCVkeHUh?=
TE-12NHK2S3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXPXOZdGUUN3ME20MlI2KG6PMnqwV2FPT0WU
NOMO-1NX;EToJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUPtbmhHUUN3ME20MlM{KG6PNEjPdZVUSU6JRWK=
RajiNXuxXoRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPwTWM2OD12LkS2JI5OMYXTRW5ITVJ?
NALM-6NXLGb4V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PGdWlEPTB;ND60PUBvVQ>?M{ntenNCVkeHUh?=
HL-60Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTwfXpKSzVyPUSuOlchdk1?MXjTRW5ITVJ?
IST-SL1MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTRwNkigcm0>MW\TRW5ITVJ?
MHH-PREB-1M3jDOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYrzeZdPUUN3ME20Mlg3KG6PNFvtcZBUSU6JRWK=
MHH-NB-11NWnzRXVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYW3fFdnUUN3ME20MlkyKG6PM17NWXNCVkeHUh?=
JiyoyeP-2003Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XESWlEPTB;NTDuUS=>NEm1WYFUSU6JRWK=
SBC-1NYXFdVlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTVwMEGgcm0>NFmwPGFUSU6JRWK=
CHP-126MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTVwME[gcm0>NU\j[ZZ4W0GQR1XS
LU-139NHfhWJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIfCXVJKSzVyPUWuNVMhdk1?MXHTRW5ITVJ?
NCI-SNU-5M1\2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnubYFKSzVyPUWuNVchdk1?MYLTRW5ITVJ?
SW962MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1Ljd2lEPTB;NT6yNUBvVQ>?NHHlNnNUSU6JRWK=
EW-1M1zCXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXmbpZSUUN3ME21MlMyKG6PNUHBcFZWW0GQR1XS
NCI-H1417NET6[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjvN2xnUUN3ME21MlUyKG6PNWfXdW12W0GQR1XS
LU-65MojDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTVwOESgcm0>MV\TRW5ITVJ?
D-502MGNXTqdm81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rufGlEPTB;Nj6zO{BvVQ>?MYjTRW5ITVJ?
BC-3NUXqUoJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;4V2lEPTB;Nj62NUBvVQ>?M1rkWXNCVkeHUh?=
GDM-1NXPEeZNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTZwN{egcm0>MlO5V2FPT0WU
NCI-H2196NX7rSGtMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELW[2tKSzVyPU[uPEBvVQ>?NUPld3VbW0GQR1XS
NB1NIPLVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjxRlF6UUN3ME22Mlg5KG6PMXXTRW5ITVJ?
NCI-H345M4HXXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7xZ2RDUUN3ME23MlIhdk1?NUXwbIdVW0GQR1XS
SU-DHL-1MnL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1:1d2lEPTB;Nz6yOEBvVQ>?MWTTRW5ITVJ?
JVM-2NWHBcY1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Moi5TWM2OD15LkK4JI5ONXqyU4tQW0GQR1XS
LU-134-AM4jId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFz3ZnlKSzVyPUeuN|khdk1?MUjTRW5ITVJ?
NCI-H1694NX;VRYhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTdwNUigcm0>NYXZdo5yW0GQR1XS
NCI-SNU-16MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XDS2lEPTB;Nz62OUBvVQ>?MVLTRW5ITVJ?
L-363NG\qXGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnTdWZIUUN3ME23Mlchdk1?NWW3cGM2W0GQR1XS
KG-1NVTCSmxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MorkTWM2OD15Lkm0JI5OMoW0V2FPT0WU
MN-60MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEK4cHZKSzVyPUiuNVQhdk1?NXLEdmFHW0GQR1XS
NB6NVfS[4I6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjOTWM2OD16LkS4JI5ONH7wdnlUSU6JRWK=
MLMAM4roNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\vPJRKSzVyPUiuPFUhdk1?NH\n[2hUSU6JRWK=
ATN-1NUn3XZdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrROnRHUUN3ME24Mlg6KG6PMnOxV2FPT0WU
SK-NEP-1MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTlwMEGgcm0>M3LVNHNCVkeHUh?=
DMS-114NHTv[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGrr[lZKSzVyPUmuOlIhdk1?MlvhV2FPT0WU
CTB-1NVOxWWtDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LRZ2lEPTB;OT62O{BvVQ>?NGPWO3BUSU6JRWK=
NCI-H2081NITVfnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVnY[nd4UUN3ME2xNE4xQSCwTR?=MV3TRW5ITVJ?
ES5MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTFyLkO4JI5ONFvKVnhUSU6JRWK=
HCC1599MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDlTWM2OD1zMT65NUBvVQ>?MUjTRW5ITVJ?
NCI-H23NGSxeJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzmS3c{UUN3ME2xNk4yOiCwTR?=MW\TRW5ITVJ?
NCI-H1581NYnyNlZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1:zUmlEPTB;MUKuNlghdk1?NX;wd|JoW0GQR1XS
JVM-3Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2fBT2lEPTB;MUKuPVkhdk1?Mne3V2FPT0WU
NCI-SNU-1NIrifHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYjmO3dqUUN3ME2xN{4yQSCwTR?=M4LaUXNCVkeHUh?=
NB7NFnve3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH7kNWVKSzVyPUG1MlkzKG6PNXvEcVY4W0GQR1XS
JARMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVz4eZlmUUN3ME2xOk4yOyCwTR?=NX;kXINzW0GQR1XS
TGWNVPOblJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NILPelZKSzVyPUG2MlQ5KG6PM1Lob3NCVkeHUh?=
U-87-MGMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWjMfVBiUUN3ME2xOk44PiCwTR?=NHeyWYtUSU6JRWK=
NCI-H1436MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnz5TWM2OD1zNz6wNUBvVQ>?MnHtV2FPT0WU
GOTOMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVvIOYFtUUN3ME2xO{4xPiCwTR?=MV3TRW5ITVJ?
COLO-800NYDHZoplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jUeWlEPTB;MUeuOlQhdk1?M2XOXHNCVkeHUh?=
MFM-223M2jIcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGW3eIZKSzVyPUG3MlkyKG6PMX;TRW5ITVJ?
EW-18M1jzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTF5Lkm2JI5OMl;jV2FPT0WU
NB14MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvVTWM2OD1zNz65PEBvVQ>?M{W2PHNCVkeHUh?=
EB2NIrL[ldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4e5ZWlEPTB;MUiuNFghdk1?NHWyOXVUSU6JRWK=
EoL-1-MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn34TWM2OD1zOD6zNUBvVQ>?M3;yWXNCVkeHUh?=
NCCITNGGxfWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3G3b2lEPTB;MUiuN|Yhdk1?M{H5SnNCVkeHUh?=
DG-75NIPCUYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkW0TWM2OD1zOD62NUBvVQ>?NYnaOnk6W0GQR1XS
HCC2218MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MonmTWM2OD1zOT61JI5OMlThV2FPT0WU
TE-6MojhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;RNGdVUUN3ME2yNE4xQCCwTR?=Ml72V2FPT0WU
SF539M1O2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jufGlEPTB;MkCuOlchdk1?M4HXXnNCVkeHUh?=
NCI-H446M2rKV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PsT2lEPTB;MkGuNVghdk1?MlvkV2FPT0WU
IST-MES1MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHe3bmlKSzVyPUKyMlc4KG6PNUjz[FBtW0GQR1XS
NCI-H82MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTJ|LkCyJI5OMnHDV2FPT0WU
HCC2157M4\BVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3vTWM2OD1{Mz6xN{BvVQ>?NEj1SHdUSU6JRWK=
EW-12M3\WSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTJ|LkG3JI5OMVTTRW5ITVJ?
SIMANH7KSW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTJ|LkO4JI5ONGDz[5VUSU6JRWK=
DOHH-2MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTJ|LkS1JI5OMmfHV2FPT0WU
IM-9NWW3UmdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjXTWM2OD1{Mz61OEBvVQ>?NIrm[|RUSU6JRWK=
EC-GI-10MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\I[5c3UUN3ME2yOE4zOyCwTR?=M{jjOHNCVkeHUh?=
HDLM-2NXLYVIhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIDlSJRKSzVyPUK0MlU1KG6PMmHRV2FPT0WU
LS-1034MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHiyPXlKSzVyPUK1Mlc2KG6PNX\3WJh2W0GQR1XS
REHM360S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTJ4LkSxJI5ONVjiPW1IW0GQR1XS
LU-165MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1P5T2lEPTB;Mk[uO|Ihdk1?MWrTRW5ITVJ?
NH-12NEi2PXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXtb|JKSzVyPUK3MlY4KG6PNWLW[2p{W0GQR1XS
WSU-NHLMmPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUL6SXZQUUN3ME2yPE4{QSCwTR?=MVfTRW5ITVJ?
ECC4NIm5ZZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\tTWM2OD1{OD63PUBvVQ>?NF\pZXBUSU6JRWK=
OCI-AML2MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\SNmxnUUN3ME2yPU43QSCwTR?=M1XnS3NCVkeHUh?=
EW-3MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnPYTWM2OD1|MD61PUBvVQ>?MnvSV2FPT0WU
NCI-H526NHGyO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVH6Nmp1UUN3ME2zNk42PCCwTR?=NFPLTJdUSU6JRWK=
NCI-H719NWD0ZnhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLpR5BzUUN3ME2zOE4{OSCwTR?=NYLNbYgyW0GQR1XS
KARPAS-422M3;K[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jQWmlEPTB;M{WuNFQhdk1?NGL2dnZUSU6JRWK=
SK-MEL-1M33Ke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1n5[GlEPTB;M{WuNVchdk1?M1vnW3NCVkeHUh?=
ES3M4G4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGq2PWpKSzVyPUO1MlE6KG6PMnP0V2FPT0WU
UACC-812MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmTETWM2OD1|NT60OEBvVQ>?MUTTRW5ITVJ?
C8166NHnPfWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlrGTWM2OD1|NT63JI5OMmXDV2FPT0WU
MDA-MB-134-VIMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTN3Lki3JI5ONY\aWohFW0GQR1XS
D-283MEDNVy4R|ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTN5Lke5JI5OM4jkTHNCVkeHUh?=
SHP-77NYHVN3kyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTN6LkCzJI5OMXnTRW5ITVJ?
NCI-H2227NYjZRlloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTRyLkS5JI5ONEGyeHdUSU6JRWK=
SKM-1NYXnN4ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPMTYlKSzVyPUSyMlY{KG6PNITLSJFUSU6JRWK=
L-428NGDTVZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjxdIdKSzVyPUSzMlg3KG6PNWjoS2RUW0GQR1XS
RPMI-6666MorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DqcGlEPTB;NEWuPFkhdk1?MVPTRW5ITVJ?
NCI-H716M1rqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHexToVKSzVyPUS4MlgyKG6PM2jQcXNCVkeHUh?=
DMS-79MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7EOGtKSzVyPUWwMlcyKG6PM{XTNnNCVkeHUh?=
RS4-11NHvxdItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLKTWM2OD13MD64PEBvVQ>?NYrtWmh4W0GQR1XS
NCI-H720M1Sxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTVzLkGxJI5OMkLvV2FPT0WU
MC-CARM{Dwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUPuO2M3UUN3ME21NU42OiCwTR?=NWnmeG1zW0GQR1XS
TALL-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTV|LkmxJI5OMnXvV2FPT0WU
NCI-N87NUDRNJFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NILufFBKSzVyPUW0MlE5KG6PNFjEdnJUSU6JRWK=
P30-OHKNVvJcG83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\F[WlEPTB;NUSuOlEhdk1?M2DlOnNCVkeHUh?=
LP-1M1znV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTZzLkK4JI5OM3fGNXNCVkeHUh?=
YTM1XqXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{LJUWlEPTB;NkGuPEBvVQ>?NFjpOJVUSU6JRWK=
MRK-nu-1MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nxcGlEPTB;NkGuPFIhdk1?MoPMV2FPT0WU
BT-474NXL2OFdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7kfI1uUUN3ME22OUBvVQ>?NGHuZXFUSU6JRWK=
NCI-H322MM3\UfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU\ORosxUUN3ME22Ok4yOSCwTR?=NE\4bXBUSU6JRWK=
NCI-H128MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vIVWlEPTB;N{SuO|chdk1?NH;rdGxUSU6JRWK=
KMS-12-PENGnwOpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\mNIxKSzVyPUe2MlI1KG6PMYnTRW5ITVJ?
KP-N-YSNYDze3JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3HWVmlEPTB;N{[uO|Qhdk1?MnPYV2FPT0WU
ALL-PONIixNXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DkcmlEPTB;N{euOlYhdk1?MU\TRW5ITVJ?
EW-13MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\5O2pKSzVyPUe3Mlc3KG6PMXXTRW5ITVJ?
EW-11MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTd6LkWyJI5ONUfGTW9OW0GQR1XS
SK-N-FIMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGi0[HFKSzVyPUiwMlIhdk1?M3\senNCVkeHUh?=
CAL-148NHfRWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWnJR|UxRThzLki0JI5ONWfUT2Q3W0GQR1XS
RLNXrDe2RUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rZOmlEPTB;OE[uNFkhdk1?MWrTRW5ITVJ?
AM-38M3TSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTh6LkC4JI5OMVrTRW5ITVJ?
RH-1NIXyOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEDtW2lKSzVyPUm5Mlg2KG6PMnXFV2FPT0WU
NCI-H1770NV\tb3l5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlHwTWM2OD1zMEKuOFkhdk1?NIDSepVUSU6JRWK=
SIG-M5M{ewT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlPkTWM2OD1zMEWuNFYhdk1?NWq2W5ZnW0GQR1XS
GR-STMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmSyTWM2OD1zMUOuN|Qhdk1?M1vCfHNCVkeHUh?=
ST486NVjPeWc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzlNmFKSzVyPUGxOE4xPiCwTR?=Ml[zV2FPT0WU
NCI-H1650NWO3N20xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn3GTWM2OD1zMUWuNlkhdk1?MX7TRW5ITVJ?
MHH-CALL-2MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3u2OWlEPTB;MUG1Mlchdk1?NGfPPYlUSU6JRWK=
BV-173MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3i1[2lEPTB;MUKyMlcyKG6PMV3TRW5ITVJ?
MC116MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX61cGZEUUN3ME2xOFgvQDVibl2=MWrTRW5ITVJ?
NCI-H524MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTF3OT6xJI5OM4XkfHNCVkeHUh?=
SCLC-21HNIn2PYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTF3OT60NUBvVQ>?MV\TRW5ITVJ?
NCI-H1304MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7LZolKUUN3ME2xOlkvOjFibl2=NHLCSoxUSU6JRWK=
NCI-H510ANHfsfnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4jmOGlEPTB;MUi1MlM4KG6PNHLpdHlUSU6JRWK=
NCI-H209M2fvXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDiTWM2OD1zOU[uOVIhdk1?NEfDUYRUSU6JRWK=
KM-H2MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWPofWV1UUN3ME2xPVcvODVibl2=Mn7RV2FPT0WU
NCI-H1395MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGL0cYFKSzVyPUKxNE4yOyCwTR?=MU\TRW5ITVJ?
NCI-H1155MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTJ|MD6zNkBvVQ>?M3Pmb3NCVkeHUh?=
COR-L279MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWfVbJB1UUN3ME2yOVIvOTdibl2=NUG2d4JrW0GQR1XS
NCI-H1299M3nZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3hTGZ5UUN3ME2yOlEvPzFibl2=M4Dle3NCVkeHUh?=
EW-22NW\PWoJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\tTmZrUUN3ME2yOlMvPzVibl2=M4C2e3NCVkeHUh?=
SK-MEL-2NYH6fFZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1zVfmlEPTB;MkixMlkhdk1?NGq0NotUSU6JRWK=
KASUMI-1NY\pcmo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTjcZFCUUN3ME2yPFMvODVibl2=NH\rNmdUSU6JRWK=
NCI-H187MnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1v3fWlEPTB;Mki3MlA5KG6PM1S1[XNCVkeHUh?=
NCI-H2171NVy2UXE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYC0[WM1UUN3ME2yPFgvQTJibl2=NF\r[HhUSU6JRWK=
LNCaP-Clone-FGCMkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLHS25KSzVyPUK5OU4zPiCwTR?=NUmweJpVW0GQR1XS
NCI-H1522MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHkfnRKSzVyPUOwO{4xPSCwTR?=Mki1V2FPT0WU
SCHM1fJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfzTWM2OD1|MkKuNlIhdk1?NI\5Z4RUSU6JRWK=
THP-1MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mor3TWM2OD1|MkKuOkBvVQ>?M2nzVHNCVkeHUh?=
SNU-C1NWiyOZl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXnNm56UUN3ME2zOlIvODlibl2=NYP2boxxW0GQR1XS
CA46M4DSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;BRnhmUUN3ME2zO|MvPjNibl2=MVzTRW5ITVJ?
NCI-H1963MnLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTN6Nj6xPUBvVQ>?Ml[0V2FPT0WU
DELNFrtdI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfKfJVKSzVyPUO5NU4zPyCwTR?=NV3Ydo4zW0GQR1XS
TURMmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4L3PWlEPTB;M{m2MlYyKG6PM3\3SXNCVkeHUh?=
NCI-H226M{\zVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFvKRVdKSzVyPUSwN{4zOyCwTR?=M1TRd3NCVkeHUh?=
COLO-668NV:wW|JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7KRlZKSzVyPUSwN{42PyCwTR?=NHfUdFBUSU6JRWK=
CPC-NNFiyVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTRyMz63O{BvVQ>?MlTRV2FPT0WU
NCI-H889M4HZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHe3bJBKSzVyPUS2NU46OiCwTR?=NFfKeYJUSU6JRWK=
J-RT3-T3-5M3HvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFG2bWpKSzVyPUWzNk42PyCwTR?=M1H3U3NCVkeHUh?=
MSTO-211HNY\r[mZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGTzRZFKSzVyPUW3OE4zPiCwTR?=NGrTPYdUSU6JRWK=
SCC-15MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XtSGlEPTB;Nk[3MlQ4KG6PNHXadZpUSU6JRWK=
SUP-T1NETw[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPVNlFnUUN3ME22PFYvODRibl2=MlfuV2FPT0WU
DMS-153Mn76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jz[mlEPTB;N{S2Mlg{KG6PMn3QV2FPT0WU
MS-1M3vJVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvBTWM2OD15NUmuOFIhdk1?MVvTRW5ITVJ?
TC-YIKNWPrTlVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVrJVnZZUUN3ME23PFEvODFibl2=M1viUXNCVkeHUh?=
RPMI-8866M1vQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWS2PGlRUUN3ME2xNFA3NjJ6IN88US=>NVnDWplMW0GQR1XS
KY821Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFuzOJNKSzVyPUGwN|YvODRizszNM{HtenNCVkeHUh?=
P31-FUJNX\QNWVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoOwTWM2OD1zMUGyMlc2KM7:TR?=MorKV2FPT0WU
COLO-824NVe1ZWhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDlTWM2OD1zMk[xMlc5KM7:TR?=MWDTRW5ITVJ?
U-698-MNYLQR3NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;MXGlEPTB;MkK2Nk4yPSEQvF2=NILlXFRUSU6JRWK=
TE-441-TM3jjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHHhVVdKSzVyPUK1NlEvPyEQvF2=M4HncHNCVkeHUh?=
IMR-5NI[0cYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTN2MEmuOlIh|ryPMWPTRW5ITVJ?
NCI-H1838NGXac3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVrpcY1[UUN3ME20NVg3NjN{IN88US=>MnfBV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]
Features

Protocol(Only for Reference)

Kinase Assay:

[4]

Kinetic Methods In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.

Cell Assay:

[5]

Cell lines Human multiple myeloma cells line U266
Concentrations ~10 μM
Incubation Time 2 days
Method

The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.

Animal Study:

[3]

Animal Models Human plasmacytoma xenografts RPMI 8226
Formulation Saline
Dosages 1 mg/kg
Administration i.v. twice weekly for 4 weeks, then once weekly

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Adams J, et al. Cancer Res, 1999, 59(11), 2615-2622.

[2] Boccadoro M, et al. Cancer Cell Int, 2005, 5(1):18.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-23)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02811978 Not yet recruiting Multiple Myeloma Janssen Research & Development, LLC September 2016 Phase 3
NCT02755597 Not yet recruiting Relapsed/Refractory Multiple Myeloma AbbVie|Genentech, Inc. June 2016 Phase 3
NCT02718833 Recruiting Multiple Myeloma Massachusetts General Hospital|Celgene|Bristol-Myers Squibb June 2016 Phase 2
NCT02719613 Not yet recruiting Multiple Myeloma Bristol-Myers Squibb|AbbVie June 2016 Phase 2
NCT02783625 Recruiting Lymphoma|Relapsed/Refractory T-cell Lymphomas Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer  ...more Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute|Stanford University May 2016 Phase 1

view more

Chemical Information

Download Bortezomib (PS-341) SDF
Molecular Weight (MW) 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms LDP-341, MLM341
Solubility (25°C) * In vitro DMSO 76 mg/mL (197.79 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name B-​[(1R)​-​3-​methyl-​1-​[[(2S)​-​1-​oxo-​3-​phenyl-​2-​[(2-​pyrazinylcarbonyl)​amino]​propyl]​amino]​butyl]​-boronic acid

Customer Product Validation(20)


Click to enlarge
Rating
Source Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck
Method Western blots
Cell Lines Primary myoblasts
Concentrations 10, 50 uM
Incubation Time 24 h
Results To demonstrate the biological functionality of the salvaged missense mutated dysferlin protein, we performed membrane resealing experiments on primary myoblasts derived from percutaneous muscle biopsies taken from patient 2. Bortezomib treatment of primary myoblasts increased dysferlin expression in a dose-dependent manner, and bortezomib-treated myoblasts regained their capability to reseal laser-induced plasma membrane injuries.

Click to enlarge
Rating
Source J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck
Method Fluorescence
Cell Lines Primary myoblasts
Concentrations 2 mg/kg
Incubation Time 2 weeks
Results To examine this further, it determined whether inhibition of the proteasome with bortezomib blocked proplatelet formation in murine megakaryocytes. Similar responses were observed in human megakaryocytes, and removal of bortezomib from the incubation media restored proplatelet formation.

Click to enlarge
Rating
Source J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck
Method Immunofluorescence
Cell Lines Mouse primary osteoblasts
Concentrations 25 nM
Incubation Time 2 h
Results In support of this idea, the PTH-induced decrease of HDAC4 accumulation in osteoblasts was prevented by the addition of an inhibitor of proteasomal degradation, bortezomib.

Click to enlarge
Rating
Source Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck
Method H&E staining, Western blots, TUNEL assays
Cell Lines Foxp3flox/yxPBCre4+ mice
Concentrations 1 mg/kg
Incubation Time 60 weeks
Results Reduced cell proliferation was also observed in prostate epithelial cells of bortezomib-treated mice by Ki67 staining analysis (A). Furthermore, lack of nuclear p65 was observed in the bortezomib-treated prostate at 12 hours after LPS injection (B). To verify the impact of bortezomib treatment on NF-kB activation, we observed the expression of NF-kB targets in the mouse prostate. In contrast to the prostate-specific expression in untreated Foxp3cKO mice, the expression levels of Bcl2l1 and Traf1/2 were significantly downregulated in the prostates of treated mice (C). Importantly, the percentage of apoptotic prostate epithelial cells increased after bortezomib treatment (D).

Click to enlarge
Rating
Source Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck
Method Immunofluorescence microscopy
Cell Lines HeLa cells
Concentrations 100 nM
Incubation Time 45 min
Results Bortezomib and NH4Cl also increased the adjacency of DRIPs to SGs.

Click to enlarge
Rating
Source Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck
Method Immunofluorescence
Cell Lines wild-type oocytes, Fmn2-/-oocytes
Concentrations 0.1 μM
Incubation Time 90 min
Results Endogenous Fmn2, localized in the cortex of prophase I oocytes, disappeared at NEBD, reappeared later and was enriched in the cortex opposite the spindle. Fmn2 -/-oocytes lacked cortical Fmn2 staining, suggesting that the staining is specific. Cortical localization was maintained at NEBD in wild-type oocytes treated with the proteasome inhibitor, Bortezomib, indicating that Fmn2 is degraded at NEBD.

Click to enlarge
Rating
Source Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck
Method Immunofluorescence Analysis
Cell Lines RS4;11cells
Concentrations 2.5 nM
Incubation Time 22 h
Results In RS4;11 samples combined treatment induces Ser536 p-NF-κB nuclear translocation (see white arrows).

Click to enlarge
Rating
Source Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck
Method Luciferase assay
Cell Lines LNCaP-AI cells, LNCaP cells
Concentrations 20 μM
Incubation Time 24 h
Results EGF significantly stimulates the promoter activity of sPLA2-IIa gene in both LNCaP and LNCaP-AI cells (shown in LNCaP-AI cells), whereas Bortezomib and other inhibitors tested downregulated the promoter activity both at the basal level (shown in LNCaP cells) and in response to EGF stimulation (shown in LNCaP-AI cells).

Click to enlarge
Rating
Source Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck
Method ELISA
Cell Lines LNCaP-AI cells
Concentrations 20 μM
Incubation Time 24 h
Results Bortezomib, Lapatinib, and LY294002 significantly inhibited sPLA2-IIa secretion, whereas Erlotinib, Gefitinib and CI-1033 had a moderate effect in LNCaP-AI cells.

Click to enlarge
Rating
Source J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck
Method Real Time PCR
Cell Lines HepAD38 cells
Concentrations 2-50 nM
Incubation Time 18 h
Results An inhibitory effect of proteasome inhibition by bortezomib on HBV replication can be observed in cell culture.Therefore, proteasome activation seems to be a valuable strategy of the infected cells to reduce the stress resulting from misfolded proteins.

Click to enlarge
Rating
Source J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck
Method Western blot
Cell Lines MA104 cells
Concentrations 0.1-10 μM
Incubation Time 1/7 h
Results Proteasome inhibitors which have different inhibition mechanisms, such as bortezomib and lactacystin, had a strong effect on virus replication in parallel with an increase in p53 accumulation.

Click to enlarge
Rating
Source J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck
Method Western blot
Cell Lines MA104 cells
Concentrations 10 μM
Incubation Time 5-10 h
Results Further kinetic experiments were performed to better define the time window within the viral replication cycle in which proteasome activity was required. For this, cells were infected for 1 h and treated with MG132 or bortezomib for 4h at different times postinfection (Fig. A). As shown in Fig. B, a more clear arrest on viral protein accumulation was observed when bortezomib or MG132 was added at relatively earlier time points. Indeed, when inhibitors were added at 5 h p.i. or later, the effect was much reduced, suggesting that once the infection was well established with a robust accumulation of viroplasms, the requirement for proteasome activity was less significant.

Click to enlarge
Rating
Source J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck
Method Immunofluorescence
Cell Lines NSP5-EGFP cells
Concentrations 10 μM
Incubation Time 2-8 h
Results Both MG132 and bortezomib induced a significant arrest on the formation of viroplasms, which appeared in reduced number and with smaller size with respect to those in control cells, particularly when added at time points between 1 h and 5 h p.i.

Click to enlarge
Rating
Source J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck
Method Quantification of viroplasms
Cell Lines NSP5-EGFP cells, MA104 cells
Concentrations 10 μM
Incubation Time 4 h
Results The number of viroplasms per cell in cells treated for 4 h with MG132 or bortezomib was almost the same as that found in cells fixed at the beginning of each treatment, strongly suggesting that inhibition of proteasome activity affected the assembly of new viroplasms and their growth.

Click to enlarge
Rating
Source J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck
Method Proteasome activity assay, Standard plaque assay
Cell Lines A549 cells
Concentrations 10-100 nM
Incubation Time 1 h
Results As expected bortezomib treatment resulted in a block of viral replication of the avian influenzavirus strain A/FPV/Bratislava/79 (H7N7; FPV) in a concentration-dependent manner. While concentrations of 10 nM had no antiviral effect, 50 nM led to a significant titer reduction of up to 3 orders of magnitude (Fig.A). The highest concentration used (100 nM) led to a titer reduction of up to 4 orders of magnitude.These results were also confirmed in a virus growth kinetics study in infected cells that received a single dose of 50nM bortezomib. Virus titers were reduced at every time point analyzed (Fig.C).Since bortezomib is a proteasome inhibitor, we investigated whether the antiviral concentrations of bortezomib may have an inhibitory effect on the 26S proteasome in A549 cells. A concentration-dependent inhibition of the proteasome was observed in FPV-infected A549 cells at 24 h p.i. (Fig. B).

Click to enlarge
Rating
Source J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck
Method Standard plaque assay, Western blot
Cell Lines A549 cells
Concentrations 50 nM
Incubation Time 1-10 h
Results A strong antiviral activity of bortezomib was observed upon addition of the compound up to 2 h p.i. At time points of 4 h p.i. and later, a dramatic decrease in the antiviral efficacy was observed. This indicates that the event in the viral life cycle that is affected by bortezomib occurs within the first 4 h. Since this correlates with the strong onset of viral gene and protein expression, we analyzed whether viral protein accumu-lation is affected by bortezomib. Indeed, we observed a strong reduction in viral matrix protein (M1) and PB1 polymerase synthesis in FPV- and PR8-infected cells at 5 h and 8 h p.i.

Click to enlarge
Rating
Source J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck
Method Western blot
Cell Lines A549 cells
Concentrations 50 nM
Incubation Time 1/6/24 h
Results After a 6-h treatment with 50 nM bortezomib, activation of JNK was detected as evidenced by phosphorylation of the kinase at Thr183 and Tyr185 (lane 4). This was even enhanced upon a 24-h treatment (lane 6). Downstream substrates of JNK are the AP-1 transcription factors c-Jun and ATF-2, which are activated by JNK-mediated phosphorylation at Ser63 and Thr71, respectively. Consistent with JNK activation, we also found c-Jun and ATF-2 were phosphorylated and activated( lane 6), leading to the conclusion that, besides NF-κB, the JNK/c-Jun/ATF-2 pathway is also activated in A549 upon bortezomib treatment.

Click to enlarge
Rating
Source PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck
Method Western blotting
Cell Lines HEK293 cells
Concentrations 50 μM
Incubation Time 4 h
Results Upon proteasome inhibition by Bortezomib an increased amount of around 5-6 fold of biotinylated molecules was detected, both in the absence and presence of US2 and US11.

Click to enlarge
Rating
Source 2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck
Method Western Blotting
Cell Lines KKU-M213 cells
Concentrations 0/20/40 nM
Incubation Time 0-12 h
Results We checked the effects of BTZ on the NF-κB pathway in KKU-M213 (Fig. a, b). BTZ induced IκB phosphorylation in dose- and time-dependent manners (Fig. a). Interestingly, reduced IκB was observed over time until it was barely detectable 12 h after treatment; as a result, nuclear NF-κB (p65) was markedly increased (Fig. b).

Click to enlarge
Rating
Source Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck
Method PB assay
Cell Lines S2-013
Concentrations
Incubation Time 24 h
Results It is noticed more deleterious effects by free bortezomib than by BTZ CS/GA nanoparticles.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Proteasome Products

  • VR23

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat(BB-2516)

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • MG-132

    MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • MLN9708

    MLN9708 immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Recently Viewed Items

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) ic50 | Bortezomib (PS-341) price | Bortezomib (PS-341) cost | Bortezomib (PS-341) solubility dmso | Bortezomib (PS-341) purchase | Bortezomib (PS-341) manufacturer | Bortezomib (PS-341) research buy | Bortezomib (PS-341) order | Bortezomib (PS-341) mouse | Bortezomib (PS-341) chemical structure | Bortezomib (PS-341) mw | Bortezomib (PS-341) molecular weight | Bortezomib (PS-341) datasheet | Bortezomib (PS-341) supplier | Bortezomib (PS-341) in vitro | Bortezomib (PS-341) cell line | Bortezomib (PS-341) concentration | Bortezomib (PS-341) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us